Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-12-06
2005-12-06
Desai, Rita (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S290000
Reexamination Certificate
active
06972295
ABSTRACT:
Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.
REFERENCES:
patent: 4973587 (1990-11-01), Ward et al.
patent: 5013837 (1991-05-01), Ward et al.
patent: 5081122 (1992-01-01), Ward
patent: 5112820 (1992-05-01), Ward
patent: 5292736 (1994-03-01), Kumar et al.
patent: 5532237 (1996-07-01), Gallant et al.
patent: 5624941 (1997-04-01), Barth et al.
patent: 6028084 (2000-02-01), Barth et al.
patent: 6344474 (2002-02-01), Maruani et al.
patent: 6355631 (2002-03-01), Achard et al.
patent: 6479479 (2002-11-01), Achard et al.
patent: 6509367 (2003-01-01), Martin et al.
patent: 0 658 546 (2001-05-01), None
patent: WO 96/33159 (1996-10-01), None
patent: WO 97/29079 (1997-08-01), None
patent: WO 98/31227 (1998-07-01), None
patent: WO 98/32441 (1998-07-01), None
patent: WO 98/33765 (1998-08-01), None
patent: WO 98/37061 (1998-08-01), None
patent: WO 98/41519 (1998-09-01), None
patent: WO 98/43635 (1998-10-01), None
patent: WO 98/43636 (1998-10-01), None
patent: WO 99/02499 (1999-01-01), None
patent: WO 00/10967 (2000-03-01), None
patent: WO 00/10968 (2000-03-01), None
patent: WO 01/09120 (2001-02-01), None
patent: WO 01/58450 (2001-08-01), None
patent: WO 01/58869 (2001-08-01), None
patent: WO 01/64632 (2001-09-01), None
patent: WO 01/64633 (2001-09-01), None
patent: WO 01/64634 (2001-09-01), None
patent: WO 01/70700 (2001-09-01), None
patent: WO 01/85092 (2001-11-01), None
patent: WO 02/28346 (2002-04-01), None
patent: WO 02/068388 (2002-09-01), None
patent: WO 02/076949 (2002-10-01), None
patent: WO 03/006007 (2003-01-01), None
patent: WO 03/007887 (2003-01-01), None
patent: WO 03/020217 (2003-03-01), None
patent: WO 03/026647 (2003-04-01), None
patent: WO 03/026648 (2003-04-01), None
patent: WO 03/027069 (2003-04-01), None
patent: WO 03/027076 (2003-04-01), None
patent: WO 03/027114 (2003-04-01), None
patent: WO 03/037332 (2003-05-01), None
patent: WO 03/040107 (2003-05-01), None
patent: WO 2004/058744 (2004-07-01), None
patent: WO 2004/060870 (2004-07-01), None
Vizi et al., Eur. J. Pharmacology (2001), vol. 431(2), pp. 237-244, “Evidence for presynaptic cannabinoid CB 1 receptor-mediated inhibition of noradrenaline release in the guinea pig lung”.
Batkai et al., Nature Medicine (2001), vol. 7(7), pp. 827-832, “Endocannabinoids activing at vascular CB 1 receptors mediate the vasodilated state in advanced liver cirrhosis”.
Schultz et al., J. Med. Chem. (1967), vol. 10, pp. 717-724, “Meleamic acids that affect plasma cholesterol and penicillin excretion”.
Pines et al., J. Med. Chem. (1967), vol. 10, pp. 725-728, “The stereochemistry of 2,3-diphenyl-1-methylpropylamine”.
Barth, Exp. Op. Therap. Patents (1998), vol. 8(3), pp. 301-313, “Cannabinoid receptor agonists and antagonists”.
Petitet et al., Emerging Drugs (1998), vol. 3, pp. 39-53, “The therapeutic applications of cannabinoid agonists and antagonists”.
Di Marzo et al., Emerging Therap. Targets (2001), vol. 5(2), pp. 241-265, “Endocannabinoids Part I: Molecular basis of endocannabinoid formation, action and inactivation and development of selective inhibitors”.
Grundy, Exp. Op. Investig. Drugs (2002), vol. 11(10), pp. 1365-1374, “The therapeutic potential of the cannabinoids in neuroprotection”.
Goya et al., Exp. Opin. Ther. Patents (2000), vol. 10(10), pp. 1529-1538, “Recent advances in cannabinoid receptor agonist and antagonists”.
Adam et al., Exp. Opin. Ther. Patents (2002), vol. 12(10), pp. 1475-1489, “Recent advances in the cannabinoids”.
Ishiwata et al., Yakugaku Zasshi, vol. 71 (1951), pp. 1272-1274, “Studies on the syntheses of isoquinoline derivatives”.
Armstrong Helen M.
Chang Linda L.
Guthikonda Ravindra N.
Hagmann William K.
Jewell James P.
Desai Rita
Fitch Catherine D.
Merck & Co. , Inc.
Winokur Melvin
LandOfFree
Substituted amides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted amides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted amides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3519012